Verona Pharma (VRNA) Stock Statistics & Valuation Metrics

Verona Pharma has a market cap or net worth of ―. The enterprise value is ―.

Verona Pharma has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Verona Pharma’s return on equity (ROE) is -0.85 and return on invested capital (ROIC) is -37.11%.

The current PE Ratio of Verona Pharma is ―. Verona Pharma’s PEG ratio is ―.

In the last 12 months, Verona Pharma had revenue of 42.28M and earned -173.42M in profits. Earnings per share was -2.16.

In the last 12 months, operating cash flow was -72.48M and capital expenditures -489.99K, giving a free cash flow of -73.03M billion.

Verona Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Verona Pharma upcoming earnings date is Nov 11, 2025, TBA (Confirmed).

Verona Pharma as a current ratio of 10.63, with Debt / Equity ratio of 87.82%

In the past 12 months, Verona Pharma has paid 6.69M in taxes.

Verona Pharma EV to EBITDA ratio is -211.10, with an EV/FCF ratio of -244.47.

Verona Pharma has $438.02M in cash and marketable securities with ― in debt, giving a net cash position of $193.64M billion.

Gross margin is 95.15%, with operating margin of -365.73%, and net profit margin of -410.18%.

The average price target for Verona Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―